Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fusion protein of tumor vascular targeted peptide and novel tumor necrosis factor

A tumor necrosis factor, tumor blood vessel technology, applied in the field of tumor blood vessel targeting peptide novel tumor necrosis factor fusion protein

Inactive Publication Date: 2009-07-15
FOURTH MILITARY MEDICAL UNIVERSITY
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are still few studies on targeting it to a certain tumor tissue or tumor neovascularization, especially for gastric cancer neovascularization, which has the second highest incidence of cancer in China, is still blank

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fusion protein of tumor vascular targeted peptide and novel tumor necrosis factor
  • Fusion protein of tumor vascular targeted peptide and novel tumor necrosis factor
  • Fusion protein of tumor vascular targeted peptide and novel tumor necrosis factor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0043] The present invention will be described in further detail below in conjunction with the accompanying drawings of the embodiments.

[0044] Example The complete sequence determination of the new tumor blood vessel-specific binding polypeptide (GX1) and the novel recombinant human tumor necrosis factor fusion gene, the PBV-GX1-rmhTNF sequencing results are as follows:

[0045] GAA TTC ATG TGT GGT AAT TCT AAT CCT AAG TCG TGC GGA TCC CGCAAA CGT AAG CCT GTA GCC CAT GTT GTA GCA AAC CCT CAA GCT GAG GGGCAG CTC CAG TGG CTG AAC CGC CGG GCC AAT GCC CTC CTG GCC AATGGC GTG GAG CTG AGA GAT AAC CAG CTG GTG GTG CCA TCA GAG GGCCTG TAC CTC ATC TAC TCC CAG GTC CTC TTC AAG GGC CAA GGC TGC CCCTCC ACC CAT GTG CTC CTC ACC CAC ACC ATC AGC CGC ATC GCC GTC TCCTAC CAG ACC AAG GTC AAC CTC CTC TCT GCC ATC AAG AGC CCC TGC CAGAGG GAG ACC CCA GAG GGG GCT GAG GCC AAG CCC TGG TAT GAG CCCATC TAT CTG GGA GGG GTC TTC CAG CTG GAG AAG GGT GAC CGA CTC AGCGCT GAG ATC AAT CGG CCC GAC TAT CTC GAC TTT GCC GAG TCT...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the pharmaceutical biotechnology field, in particular relates to gene cloning, expression of an exogenous gene in a procaryotic cell, purification of target protein, and novel tumor necrosis factor fusion protein of tumor blood vessel targeted peptide. The invention is characterized in that a small bacteriophage peptide capable of being specifically combined with a blood vessel with gastric cancer is obtained by applying a bacteriophage peptide library in vivo screening technology, and is fused into Escherichia coli together with a novel human tumor necrosis factor alpha (rmhTNF) to obtain high-level expression, the target protein is purified by ammonium sulfate salting-out or an anion-cation exchange method, and the obtained target protein is subject to an activity test. The target protein has the advantages of high efficiency and low toxicity of a novel recombinant human tumor necrosis factor, and can gather in a new blood vessel of a gastric cancer tissue, thus further lowering the clinical dosage for the human tumor necrosis factor, improving the dosage-effect ratio and lowering the toxic and side effect during gastric cancer treatment.

Description

technical field [0001] The invention belongs to the technical field of medicine and biology, and specifically relates to gene cloning, expression of exogenous genes in prokaryotic cells, purification of target proteins, and novel tumor necrosis factor fusion protein of tumor blood vessel targeting peptide. Background technique [0002] Related research and existing problems of tumor angiosuppressive therapy: [0003] Tumor angiogenesis is a prerequisite for rapid tumor proliferation, and inhibiting tumor angiogenesis is an important approach for tumor treatment. At present, the tumor vasculature suppression therapy mainly includes the following approaches: ①Blocking the regulatory factors that promote angiogenesis. Vascular growth stimulating factors such as VEGF are the most commonly found pro-angiogenic growth factors in tumor cells, and they are also the main target molecules in vascular therapy. ②Enhance the regulatory factors that inhibit the growth of blood vessels. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K19/00C12N15/62C12N15/70A61K38/16A61K49/00A61P35/00
Inventor 吴开春张英起曹珊珊
Owner FOURTH MILITARY MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com